Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments mainstream.
…To date, Doudna and the Institute have helped spin out 31 companies that are now valued at around $9 billion and employ more than 2,500 people. She is a cofounder of seven of them. For these achievements, Forbes has named Doudna to our list of America’s 250 Greatest Innovators.
